Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Bayer: Kmart bankruptcy, coupled with slow cough/cold season, 70% consumer sales dive in Argentina contribute to 9% drop in consumer care revenue to $449 mil. (€1 = $.8979) in the first quarter. Overall, Bayer health care sales dipped 5.5% to $2.16 bil., largely due to withdrawal of cholesterol-lowering drug Baycol last August (1"The Tan Sheet" Aug. 13, 2001, In Brief). Net income rose 18.3% to $469.6 mil. for the quarter, firm says...

You may also be interested in...

Herbalife Buyout By Equity Groups Achieves Long-Sought Private Ownership

The pending acquisition of Herbalife by equity firms Whitney & Co. and Golden Gate Capital ends a two-and-a-half year effort, initiated by late founder and CEO Mark Hughes, to take the direct marketer private

Statin adverse event?

Bayer withdraws Rx cholesterol-lowering statin Baycol (cerivastatin) due to prevalence of rhabdomyolysis, including 31 fatal cases, at low doses, FDA says Aug. 8. Agency suggests Baycol users talk to doctors about switching to alternative statins, including Merck's Mevacor and BMS' Pravachol, both of which were subject to OTC switch consideration last summer (1"The Tan Sheet" July 17, 2000, pp. 3-6). Public Citizen plans to petition FDA to include "black box" warning on all Rx statins informing patients of serious adverse event risks, group says

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts